Technical Snapshots for These Biotech Stocks -- CorMedix, iBio Inc., ImmunoCellular Therapeutics, and Protalix BioTherapeutics

Monday, October 30, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 30, 2017 /PRNewswire/ --

If you want a Stock Review on CRMD, IBIO, IMUC, or PLX then come over

to and sign up for your free customized report. has initiated coverage on CorMedix Inc. (NYSE AMER: CRMD), iBio Inc. (NYSE AMER: IBIO), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC),
and Protalix BioTherapeutics Inc. (NYSE: AMER: PLX). Companies in the Biotech space are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct R&D. Access's complimentary reports for today's stocks line-up at:


Bridgewater, New Jersey-based CorMedix Inc.'s stock finished last Friday's session 2.12% higher at $0.58. A total volume of 465,161 shares was traded. The Company's shares have advanced 17.96% in the past month and 55.25% over the previous three months. The stock is trading above its 50-day moving average by 12.94%. Additionally, shares of CorMedix, which focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the US and other markets, have a Relative Strength Index (RSI) of 50.09.

On October 26th, 2017, CorMedix announced that Bruce Reidenberg, M.D., Adjunct Assistant Professor of Pharmacology at Weill Cornell Medicine, will make an oral presentation titled, "Multi-Resistant Candida auris is Susceptible to Taurolidine," at the 2nd Annual Gulf Congress of Clinical Microbiology and Infectious Diseases, which will be held from November 01st, 2017, to November 04th, 2017, in the Kingdom of Bahrain. Visit us today and access your complete report on CRMD for free at:

iBio Inc. 

On Friday, shares in New York-based iBio Inc. ended the session 0.22% higher at $0.32. The stock recorded a trading volume of 217,846 shares. The Company's shares have gained 2.32% in the last one month and 2.32% in the previous three months. The stock is trading 0.73% above its 50-day moving average. Moreover, shares of iBio, which focuses on developing and commercializing pharmaceutical product applications using its platform in the US and internationally, have an RSI of 47.79.

On October 02nd, 2017, iBio announced the appointment of James Abbey, Ph.D. as Vice President of Strategic Business Development. Dr. Abbey's background includes in-depth experience and leadership of strategic partnership and growth opportunities for major medical research and development institutions. Prior to joining the Company, he served as the Director for Global and Corporate Partnerships for the Texas A&M University System, where he established and managed key collaborations with major global organizations across industry and academia. The complimentary research report on IBIO can be accessed at:

ImmunoCellular Therapeutics 

Calabasas, California-based ImmunoCellular Therapeutics Ltd's shares declined 1.44%, closing the session at $0.38 with a total trading volume of 1.42 million shares. The stock has gained 3.51% in the last one month and 9.43% over the previous three months. The stock is trading 10.73% above their 50-day moving average. Additionally, shares of ImmunoCellular Therapeutics, which develops immune-based therapies for the treatment of various cancers, have an RSI of 52.65. Register for free on and download the research report on IMUC at:

Protalix BioTherapeutics 

Last Friday at the close, shares in Karmiel, Israel-based Protalix BioTherapeutics Inc. recorded a trading volume of 555,880 shares. The stock ended the session 1.73% lower at $0.71. The Company's shares have advanced 20.37% in the past month, 5.15% over the previous three months, and 60.67% since the start of this year. The stock is trading above its 50-day moving average by 18.60%. Furthermore, shares of Protalix BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have an RSI of 58.33.

On October 18th, 2017, Protalix BioTherapeutics ("PLX") announced an Ex-US license and collaboration agreement with Chiesi Farmaceutici S.p.A. ("Chiesi") for pegunigalsidase alfa ("PRX-102")-PLX's chemically modified version of the recombinant protein alpha-Galactosidase-A protein that is currently being evaluated in phase-III clinical trials for the treatment of Fabry disease. PRX-102 has demonstrated a significantly enhanced circulatory half-life and higher enzyme activity in the target organs affected by Fabry disease when compared to currently available versions of the molecule, and strong positive safety and efficacy data from its completed phase-I/II clinical trial. Get free access to your research report on PLX at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store